OACCW · Oaktree Acquisition Corp. III Life Sciences · Executive Compensation
$0.91
At close · Oct 20
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 12, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Such potential liquidity shortfalls and mandatory liquidation condition raise substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 12, 2026
Market Cap
$262.05M
Shares
24.58M
Volume · Oct 20
570
Avg daily vol (3M)
9097
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
No Compensation Data
No Summary Compensation Table has been imported from this company's proxy statements yet.
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| George A. Martinez | Chief Financial Officer (principal accounting and principal financial officer) | Appointed | 2025-10-29 |
| Thomas Sweeney | Chief Financial Officer | Resigned | 2025-10-29 |
| David A. Berry, MD, PhD | independent director | Appointed | 2025-10-17 |
| Thomas Sweeney | Chief Financial Officer (principal accounting and principal financial officer) | Appointed | 2025-06-06 |
| Courtney Conigliaro | Chief Financial Officer | Resigned | 2025-06-06 |
| Zaid Pardesi | director of the Company | Appointed | 2025-01-07 |
| Aman Kumar | chairman of the Board | Appointed | 2025-01-07 |
| John Frank | board of directors | Resigned | 2025-01-07 |
Leadership
- Aman Kumar Chairman
- George A. Martinez CFO
- Thomas Sweeney CFO
- David A. Berry Board Member
- David A. Berry, MD, PhD Board Member
- Zaid Pardesi Board Member